Abstract 465P
Background
Diffuse intrinsic pontine glioma (DIPG) is one of the most aggressive pediatric central nervous system tumors, and currently, there are no curative treatment options available. With the increasing application of molecular diagnostics, more and more DIPG patients are recommended to undergo surgery; however, its correlation with dissemination needs to be better understood. Hence, we conducted this cohort to analyze the predictors of subsequent metastasis in pediatric DIPGs.
Methods
The final analysis included 142 pediatric (age ≤ 12) DIPG patients treated at Sanjiu Brain Hospital between January 2017 and September 2023. The data were retrospectively collected following the initial diagnosis. Patients were followed up for 6 months. The primary endpoint was the occurrence of subsequent metastasis. Univariable and multivariable logistic regression analyses were utilized to identify statistically significant predictors of subsequent dissemination. All statistical assessments were two-tailed, and only P < 0.05 was deemed to be statistically significant.
Results
Among 142 patients, 14 (9.9%) developed metastasis within the follow-up time. There were 77 (54.2%) males and 65 (45.8%) females. The median age was 7 years (ranging 1 - 12 years). The overall cohort demonstrated that surgery was the only predictor of dissemination both in univariable (OR 4.567, 95%CI 1.351 – 20.901, P = 0.024) and multivariable (OR 5.501, 95%CI 1.560 – 26.105, P = 0.014) analyses. However, subgroup analysis involving patients who received surgical intervention showed that biopsy was not superior nor inferior to resection in terms of relative risk for subsequent dissemination (16.7% vs. 15.8%).
Conclusions
Surgical intervention increases the relative risk of dissemination occurrence to four times more than those who did not receive surgery. Surgical intervention is crucial given the potential of molecular analysis leading to improved therapeutic options. Nonetheless, patients should be informed about the risks associated with surgery, including subsequent metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
479P - The candidate novel markers PIV and PILE score to predict survival outcomes and therapeutic response in patients with primary central nervous system lymphoma
Presenter: Ling Duan
Session: Poster session 16
Resources:
Abstract
480P - Clinical utility of ctDNA detection by NGS for diagnosis of CNS lymphoma
Presenter: Ana Jiménez-Ubieto
Session: Poster session 16
481P - Integrating GWAS and transcriptomics prioritizes drug targets for meningioma
Presenter: Wan-Zhe Liao
Session: Poster session 16
482P - The prognostic impact of CDKN2A/B heterozygous deletions in meningioma: Insights of a multicenter analysis
Presenter: Franziska Ippen
Session: Poster session 16
483P - The use of steroids associated with PD1/PDL-1 blockage in patients with brain metastasis: A systematic review and meta-analysis
Presenter: Francisco Cezar Moraes
Session: Poster session 16
484P - EGFR amplification is the potential driver gene that accelerates brain metastases in NSCLC patients
Presenter: Hainan Yang
Session: Poster session 16
485P - A spatio-temporal evolution mathematical model of glioma growth: The influence of cellular and nutrient interactions on the tumor microenvironment
Presenter: Kalysta Borges
Session: Poster session 16
486P - Effects of a BBB-penetrating oligonucleotide drug, RBD8088, in mouse models of human glioblastoma
Presenter: Julia Grönros
Session: Poster session 16
487P - 3D-bioprinted co-cultures of glioblastoma and mesenchymal cells indicate a role for perivascular niche cells in shaping the chemotactic tumour microenvironment
Presenter: Radosław Zagożdżon
Session: Poster session 16
488P - ITGA2 promotes glioma cell stemness and progression by activating the AKT pathway
Presenter: Lihui Wang
Session: Poster session 16